Body mass index evolution and ovarian function in adolescent girls who received GnRH agonist treatment for central precocious puberty or early and fast puberty
Journal of Pediatric Endocrinology and Metabolism, cilt.36, sa.11, ss.1044-1051, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 11
- Basım Tarihi: 2023
- Doi Numarası: 10.1515/jpem-2023-0232
- Dergi Adı: Journal of Pediatric Endocrinology and Metabolism
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, MEDLINE
- Sayfa Sayıları: ss.1044-1051
- Anahtar Kelimeler: precocious puberty, early and fast puberty, gonadotropin-releasing hormone agonist, anti-Mullerian hormone, polycystic ovary syndrome
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: Gonadotropin-releasing hormone agonist (GnRHa) has been used for central precocious puberty (CPP) or early and fast puberty. It was aimed to assess changes in body mass index (BMI), polycystic ovary syndrome (PCOS) frequency, and anti-Mullerian hormone (AMH) in girls who had been treated with GnRHa. Methods: Fifty-eight adolescent girls treated with GnRHa for CPP or early and fast puberty (3.75mg/28 days), between 2011 and 2015, were re-evaluated in 2020-2022 at least 2 years after menstruation. Hormonal analyses were compared with 51 healthy adolescents. Results: In the GnRHa-treated group, a statistically significant increase was observed when the BMI standard deviation score (SDS) at the beginning of the treatment was compared with the BMI SDS at the end of the treatment (p=0.038). A statistically significant decrease was observed when the BMI SDS at the end of the treatment was compared with the BMI SDS in late adolescence (p=0.012). When the BMI SDS at the beginning of the treatment was compared with the BMI SDS in late adolescence, it was observed that there was no statistically significant difference (p=0.196). Of the 58 girls in the GnRHa-treated group, 8 (14%) had PCOS. Serum AMH levels did not differ between the GnRHa-treated and the control group. Conclusions: GnRHa treatment causes no adverse effect on BMI, at least in late adolescence. Girls treated with GnRHa were not found to be prone to developing PCOS. AMH levels were similar in the GnRHa-treated group as in the control group.